Summary.-The formation of cyclic AMP was studied in normal liver, subcutaneous hepatomas derived from MH1C1 cells, and premalignant liver and primary hepatomas induced by the carcinogens 2-acetylaminofluorene (AAF) and 4-dimethylamino-azobenzene (DAB). While only very slight effects of prostaglandins (PG) were seen in slices of normal liver, all the hepatomas responded strongly to PGE1 and PGE2. The hepatomas also had increased PGE,-sensitive adenylate-cyclase activity. PGFia and PGF2as did not increase the cAMP level significantly either in the liver or in the hepatomas. During AAF carcinogenesis the response to PGE1 increased slightly during the carcinogen feeding, and was greatly elevated only in the fully developed hepatomas. This is in contrast to the increase in adrenalin response seen during carcinogenesis, which starts much earlier, and reaches a peak value within 8-10 weeks. It is concluded that various hepatomas have elevated responsiveness to PGE1 and PGE2 as well as to adrenalin, but the course of change in the tissues' ability to respond to these agents during carcinogenesis is very different.
Summary.-The formation of cyclic AMP was studied in normal liver, subcutaneous hepatomas derived from MH1C1 cells, and premalignant liver and primary hepatomas induced by the carcinogens 2-acetylaminofluorene (AAF) and 4-dimethylamino-azobenzene (DAB). While only very slight effects of prostaglandins (PG) were seen in slices of normal liver, all the hepatomas responded strongly to PGE1 and PGE2. The hepatomas also had increased PGE,-sensitive adenylate-cyclase activity. PGFia and PGF2as did not increase the cAMP level significantly either in the liver or in the hepatomas. During AAF carcinogenesis the response to PGE1 increased slightly during the carcinogen feeding, and was greatly elevated only in the fully developed hepatomas. This is in contrast to the increase in adrenalin response seen during carcinogenesis, which starts much earlier, and reaches a peak value within 8-10 weeks. It is concluded that various hepatomas have elevated responsiveness to PGE1 and PGE2 as well as to adrenalin, but the course of change in the tissues' ability to respond to these agents during carcinogenesis is very different.
CYCLIC AMP (cAMP) seems to be a regulator of cell growth, but its precise role is incompletely understood (Ryan & Heidrick, 1974; Pastan et al., 1975; Friedman, 1976) . The metabolism of cAMP is altered in many cancers and malignant cell lines. In rat hepatomas the cAMP system is regulated differently from that of normal liver tissue. In most hepatomas adenylate cyclase is less responsive to glucagon than the liver enzyme (Allen et al., 1971; Emmelot & Bos, 1971; Christoffersen et al., 1972; Tomasi et al., 1973; Boyd et al., 1974; Hickie et al., 1975; Criss & Morris, 1976; Hickie et al., 1977) . However, increased effects of adrenalin (Brown et al., 1970; Christoffersen et al., 1972; Boyd et al., 1974) and prostaglandin E1 (PGE1) (Chayoth et al., 1973) have also been described. Furthermore, during treatment of rats with chemical carcinogens, before tumour development, alterations in the response pattern of the adenylate cyclase have been observed, including increased responsiveness to adrenergic agents (Christoffersen et al., 1972 (Christoffersen et al., , 1974 Christoffersen, 1975; Boyd et al., 1974 Boyd et al., , 1976 and to PGE1 (Chayoth et al., 1973) .
The present study was undertaken in order to get more information on how control of cAMP formation differs in hepatomas and livers. Particular interest has been devoted to the effect of prostaglandins, which have also been proposed as taking part in growth regulation (Sykes, 1976; Jimenez de Asua et al., 1975; Hial et al., 1976) . Some primary and transplanted hepatomas were studied, to see whether the increased responsiveness to PGE1 that has been reported for ethionine-induced hepatomas (Chayoth et al., 1973) (Christoffersen, 1975) . This diet was supplemented with 0-0250o AAF for the treated group. Pairfed control animals received the basal diet. Liver tissue designated as pre-malignant was taken from rats killed at various times of treatment, before development of tumours. After 8 inonths the carcinogen treatment was terminated, and the animals were given standard laboratory chowt, until they were killed 5 months later. At that time, the mnajority of treated rats had liver tumours, often multiple nodules of varying diameter. Tunmours of diameter 0-5-1P5 cm were used in the experiments described here. The ttamours were examined histologically (courtesy of Dr S. B. Refsum, Rikshospitalet, Oslo), and were found to be hepatocareinomnas. We also studied a single tumour from a rat treated wiith 0-0500 DAB for 7 months, followed by 9 months on carcinogen-free diet.
Inoculation of hepatoma cells.-Buffalo rats of either sex xwere used in these experiments. The clonal rat hepatoma cell line MH1C1 derived from Morris hepatoma 7795 (Richardson et al., 1969) was cultured as described by Gaudernack et al. (1973 by the addition of the agents to be tested dissolved in 0-5 ml of the Krebs-Ringer bicarbonate buffer with 8mM theophylline, to give a final volume of 2 ml, and concentrations as indicated in the figure legends.
Stock solutions of prostaglandins were dissolved in 96% ethanol (2 mg/ml) and diluted in buffer immediately before addition. The incubation was terminated by rapidly transferring the slice to liquid N2 after blotting on filter paper.
The frozen slices were homogenized in 500 trichloroacetic acid. Cyclic AMP was determined as described earlier (Christoffersen et al., 1973) using the protein-binding assay of Gilman (1970 Table I shows the levels of cAMP in slices from various hepatomas after exposure to adrenalirn, glucagon or PGE1. In one series of experiments, MH11C1-derived tumours were compared with liver from tumour-bearing animals. In the liver slices neither adrenalin nor PGE1 showed any effect, while glucagon increased the cAMP level about 5-fold in 2 min. In contrast, the slices prepared from subcutaneous MH1Cl-derived hepatomas or mesenterial metastases from these tumours responded strongly to adrenalin (4-5-fold) and to PCE1 (10-fold), but only slightly to glucagon (40%0 increase).
Similarly, primary hepatomas, induced by AAF or DAB feeding, responded very strongly to adrenalin or PGE1, compared to the slight effects of these agents on the cAMP content in slices from the adjacent uninvolved liver tissue. These primary hepatomas differed from the MHlClderived tumours in that most of them were markedly responsive to glucagon. Dose-response curves for various prostaglandins on cAMP levels in slices from liver and MH1C1-derived tumours are given in Fig. 1 . The figure shows the striking difference between the liver and the hepatoma in responsiveness to PGE1 and PGE2. PGF1 a and PGF2 a had no significant effect on any of the tissues. (Table I) . We have no explanation for this discrepancy, which was seen also for the adrenalin Christoffersen et al., 1974) . It is a wellknown phenomenon that a large part of the adenylate-cyclase response towards hormones maybe lost ontissue homogenization (Achar et al., 1977) , possibly owing to membrane derangement or non-optimal composition of the incubation mixture in broken-cell preparations.
In the present case, additional evidence that the very strong effect of PGE1 on cAMP accumulation in the hepatoma tissue is actually due to adenylatecyclase activation, was obtained in experiments (Table III) showing that the increase in cAMP content in slices after PGE1 could be amplified by theophylline, and even more so by the more potent phosphodiesterase inhibitor, methyliso- PGE1 responsiveness in slices during AAF-carcinogenesis is shown in Fig. 2 . As (Christoffersen et al., 1974) , the adrenalin response increased rapidly during the first weeks, reaching a maximum at about 8 weeks. It then declined, as has also been found during 3'-methyl-DAB carcinogenesis (Boyd et al., 1974 (Boyd et al., , 1976 , but in the final hepatoma the response to adrenalin was still greater than in normal liver tissue (Fig.  2) .
The PGE1 response increased slowly during the carcinogen treatment, but was greatly increased in the hepatomas. This is in accordance with the observations of Chayoth et al. (1973) , who found increased response to PGE1 during ethionine carcinogenesis, before and after hepatoma development. However, in the present work we show that the changes in adrenalin and PGE1 response take completely different courses during the carcinogen treatment (Fig. 2) . (50pg/ml) (25 ,ug/ml) (Chayoth et al., 1973) . In our experiments we found that PGE2 was also strongly stimulatory, while PGF1 a and PGF2 <, had no significant effect on the cAMP level.
The data presented here also show that the responsiveness to adrenalin and PGE1 develops very differently during the carcinogenic process. It has previously been shown that during liver carcinogenesis the adrenalin responsiveness increases during the first weeks of carcinogen treatment (Christoffersen et al., 1972 (Christoffersen et al., , 1974 Boyd et al., 1974 Boyd et al., , 1976 ).
After 7-12 weeks the responsiveness decreases (Boyd et al., 1974 (Boyd et al., , 1976 , but in the final hepatomas the adrenalin responsiveness is still greater than in normal liver. This pattern was confirmed in the present study (Fig. 2) . In contrast, the increased PGE1 effect appeared much later and was not maximal until hepatomas had developed (Fig. 2) . AVe do not know exactly at which stage the increased 4 PGE1 responsiveness appears. In general, it is still not known whether changes in cell properties seen after malignant transformation result from continuous alterations during the process of carcinogenesis.
The interpretation of the present results, in terms of understanding the role of prostaglandins in the biology ofhepatomas, is difficult at present. One problem is that although all the hepatomas investigated in the present study were strongly responsive to PGE1 and PGE2, we do not know so far whether this is a property of the hepatoma cells or of some other cell type in the tumour. We investigated whether the effects of PGE1 and glucagon on premalignant liver were additive. The interpretation of these experiments, however, was hampered by the fact that PGE1 inhibited the glucagon effect on cAMP accumulation, as has previously also been seen in normal rat liver in vivo (DeRubertis et al., 1974) . Therefore, these experiments did not give a final answer to the important question of the cellular localization of the increase in prostaglandin responsiveness in liver tissue during hepatoma development. The role of a prostaglandin-mediated increase of cAMP in hepatoma cells is also unclear. Cyclic AMP levels are high in various hepatomas (Thomas et al., 1973; as well as in liver tissue under conditions of rapid proliferation, such as in the neonatal period (Christoffersen et al., 1973) and during regeneration (McManus et al., 1972) . Under appropriate conditions, cAMP administration leads to initiation of liver DNA synthesis in vivo (Short et al., 1975) . Prostaglandins have been proposed as positive as well as negative regulators of cell proliferation (Sykes, 1976; Jimenez de Asua et al., 1975; Feher & Gridali, 1974; Thomas et al., 1973) . In foetal hepatocyte cultures, PGE1 has been shown to enhance incorporation of 3H-thymidine into DNA (Leffert et al., 1976) . Increased responsiveness to prostaglandins could therefore play a role in the phenotypic expression of the malignant state of some cancers.
